Literature DB >> 30528825

Cochrane Reviews and Dermatological Trials Outcome Concordance: Why Core Outcome Sets Could Make Trial Results More Usable.

Jochen Schmitt1, Toni Lange2, Jan Kottner3, Cecilia A C Prinsen4, Tobias Weberschock5, Elisabeth Hahnel3, Christian Apfelbacher6, Susanne Brandstetter6, Andreas Dreher7, Giles Stevens2, Esther Burden-Teh8, Natasha Rogers8, Phyllis Spuls9, Matthew J Grainge10, Hywel C Williams8, Lena Jacobi2.   

Abstract

Evidence-based health care requires that relevant outcomes for patients are included in clinical trials investigating treatment effects, allowing subsequent systematic reviews to summarize all relevant evidence to guide clinical practice. Currently, no gold standard of outcome choice for dermatology trials and reviews exists. We systematically assessed concordance between efficacy outcomes in a random sample of 10 Cochrane Skin systematic reviews and the 220 dermatology trials included. Reviews did not include 742 (68%) of the 1,086 trial outcomes. Of the 60 outcomes the reviews sought, 17 (28%) were not reported in any trial, while 12 were assessed in <50% of trials. For 11 of 23 (48%) primary review outcomes, meta-analysis was impossible, because trial outcomes were absent or unclear. This small overlap of review/trial outcomes could suggest that trials are not measuring the outcomes perceived to be the most important by patients, clinicians, systematic reviewers, and trialists. The lack of standardized outcome measures, poor reporting of outcomes in trials, and low concordance of outcomes between reviews and primary studies could be improved by the development and implementation of Core Outcome Sets. These are an agreed-upon minimum set of key outcomes, for specified conditions, to be reported in all trials.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30528825     DOI: 10.1016/j.jid.2018.11.019

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  2 in total

1.  Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2.

Authors:  A C Fledderus; S G M A Pasmans; A Wolkerstorfer; W Oei; H C Etchevers; M S van Kessel; C M A M van der Horst; P I Spuls
Journal:  Br J Dermatol       Date:  2021-07-14       Impact factor: 11.113

2.  A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis.

Authors:  Francisco Gómez-García; Pedro Jesús Gómez-Arias; Ana Montilla-López; Jorge Hernández-Parada; Juan Luís Sanz-Cabanillas; Juan Ruano; Esmeralda Parra-Peralbo
Journal:  Front Med (Lausanne)       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.